Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment

British Journal of Clinical Pharmacology

Volumn 83, Issue 9, 2017, Pages 1944-1953

  Kropeit, Dirk ^a   Scheuenpflug, Jürgen ^a   Erb Zohar, Katharina ^b   Halabi, Atef ^c   Stobernack, Hans Peter ^a   Hulskotte, Ellen G J ^d   van Schanke, Arne ^e   Zimmermann, Holger ^a   Rübsamen Schaeff, Helga ^a  

^a AiCuris GmbH   (Germany)

^b Clinphase   (Germany)

^c CRS Clinical Research Services Kiel GmbH   (Germany)

^d MSD   (Netherlands)

^e MSD Oss BV   (Netherlands)

Author keywords

antivirals; cytomegalovirus; letermovir; pharmacokinetics; renal insufficiency

Indexed keywords

LETERMOVIR; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MODERATE RENAL IMPAIRMENT; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RENAL CLEARANCE; SEVERE RENAL IMPAIRMENT; UNBOUND FRACTION; BLOOD; CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; MIDDLE AGED;

ACETATES; AGED; ANTIVIRAL AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RENAL INSUFFICIENCY;

EID: 85018414146     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13292     Document Type: Article

References (34)

1. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14: 633–641.
2. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis 1999; 1: 165–178.
3. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010; 24: 319–337.
4. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27: 877–881.
5. Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect 1995; 10: 209–215.
6. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010; 50: 1439–1447.
7. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20: 202–213.
8. Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: A promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist 2015; 8: 269–277.
9. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67: 1417–1425.
10. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997; 90: 2502–2508.
11. Marty FM, Winston D, Rowley SD, Boeckh M, Vance E, Papanicolaou G, et al. CMX001 for prevention and control of CMV infection in CMV-seropositive allogeneic stem-cell transplant recipients: A phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of safety, tolerability and antiviral activity. Biol Blood Marrow Transplant 2012; 18: S203–S204.
12. Chimerix. Chimerix announces top-line results from phase 3 SUPPRESS trial of Brincidofovir. Available at http://ir.chimerix.com/releasedetail.cfm?releaseid=948172. Updated 2015 (last accessed 18 February 2016).
13. Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, et al. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol 2001; 75: 9077–9086.
14. Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001; 48: 757–767.
15. Weber O, Bender W, Eckenberg P, Goldmann S, Haerter M, Hallenberger S, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res 2001; 49: 179–189.
16. Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011; 11: 1079–1084.
17. Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M, et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014; 27: 77–86.
18. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884–10893.
19. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290–1297.
20. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370: 1781–1789.
21. Marty FM, Ljungman PT, Chemaly RF, Maertens JA, Snydman DR, Duarte RF, et al. A phase III randomized, double-blind, placebo-controlled trial of Letermovir (LET) for prevention of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). Paper presented at the BMT Tandem Meetings 2017, 2017.
22. AiCuris Anti-infective Cures GmbH. Unpublished data on file. 2009.
23. Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 2014; 85: 522–528.
24. FDA. Guidance for industry: pharmacokinetics in patients with impaired renal function — Study design, data analysis, and impact on dosing and labeling. 2010.
25. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200841.pdf. Updated 2015 (last accessed 16 August 2016).
26. AiCuris Anti-infective Cures GmbH. Unpublished data on file. 2005.
27. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 2008; 36: 124–128.
28. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP 1991; 25: 1214–1224.
29. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142–150.
30. Wynne HA, Goudevenos J, Rawlins MD, James OF, Adams PC, Woodhouse KW. Hepatic drug clearance: The effect of age using indocyanine green as a model compound. Br J Clin Pharmacol 1990; 30: 634–637.
31. Fujita KI, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, et al. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res 2016; 33: 269–282.
32. Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974; 15: 276–282.
33. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 2013; 52: 1–8.
34. Lalande L, Charpiat B, Leboucher G, Tod M. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet 2014; 53: 521–532.